Overcoming obstacles in Parkinson's disease

Factors Influencing Physician Referrals of Patients to Clinical Trials

(2015) Arch G. Mainous et al.   JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome study

(2012) Andrew Siderowf et al.   MOVEMENT DISORDERS

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

(2012) I. H. Richard et al.   NEUROLOGY

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

(2012) P. A. LeWitt et al.   NEUROLOGY

Assessing Research Participants’ Perceptions of their Clinical Research Experiences

(2011) Rhonda G. Kost et al.   CTS-Clinical and Translational Science

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

(2011) Martin C. Herzig et al.   HUMAN MOLECULAR GENETICS

Enhanced Phosphatase Activity Attenuates  -Synucleinopathy in a Mouse Model

(2011) K.-W. Lee et al.   JOURNAL OF NEUROSCIENCE

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

What motivates Parkinson’s disease patients to enter clinical trials?

(2011) Anabela Valadas et al.   PARKINSONISM & RELATED DISORDERS

Animal models of Parkinson's disease

(2011) Vernice Jackson-Lewis et al.   PARKINSONISM & RELATED DISORDERS

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

Deep Brain Stimulation for Parkinson Disease

(2010) Jeff M. Bronstein et al.   ARCHIVES OF NEUROLOGY

Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations

(2010) Carlo Colosimo et al.   MOVEMENT DISORDERS

Defining disease-modifying therapies for PD-A road map for moving forward

(2010) C. Warren Olanow et al.   MOVEMENT DISORDERS

α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra

(2010) Alison L. McCormack et al.   PLoS One

Motor Phenotype of LRRK2 G2019S Carriers in Early-Onset Parkinson Disease

(2009) Roy N. Alcalay et al.   ARCHIVES OF NEUROLOGY

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

(2009) R. Jeremy Nichols et al.   BIOCHEMICAL JOURNAL

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model

(2009) Ana Muñoz et al.   EXPERIMENTAL NEUROLOGY

Genome-wide association study reveals genetic risk underlying Parkinson's disease

(2009) Javier Simón-Sánchez et al.   NATURE GENETICS

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

(2009) E. Sidransky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigation of leucine-rich repeat kinase 2

(2008) Vasanti S. Anand et al.   FEBS Journal